Trial Profile
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Diabetic neuropathies; Fibromyalgia
- Focus Therapeutic Use
- Acronyms ExPAND
- Sponsors Pfizer
- 06 Jun 2012 Actual patient number (42) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.